2003
Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection
Royal W, Vlahov D, Lyles C, Gajewski C. Retinoids and Drugs of Abuse: Implications for Neurological Disease Risk in Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases 2003, 37: s427-s432. PMID: 14648459, DOI: 10.1086/377554.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 (HIV-1) infectionVirus type 1 infectionType 1 infectionDrug usersSeronegative control subjectsRetinoic acidDevelopment of HIVInjection drug usersTumor necrosis factorNervous system diseasesLevels of retinolMononuclear cell lineNeurological disease riskTrans retinoic acidDrugs of abuseRetinoid administrationClinical outcomesRetinol-binding proteinImmunomodulatory effectsControl subjectsNecrosis factorSystem diseasesNeurological diseasesHIVDisease risk
1991
HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users.
Royal W, Updike M, Seines O, Proctor T, Nance-Sproson L, Solomon L, Vlahov D, Cornblath D, McArthur J. HIV-1 infection and nervous system abnormalities among a cohort of intravenous drug users. Neurology 1991, 41: 1905-10. PMID: 1745346, DOI: 10.1212/wnl.41.12.1905.Peer-Reviewed Original ResearchConceptsHIV-1 serostatusIntravenous drug usersNeurologic abnormalitiesDrug usersSeronegative intravenous drug usersCD4 cell countHIV-seropositive subjectsHIV-1 infectionNervous system abnormalitiesConstitutional symptomsElectrophysiologic evaluationSeropositive participantsSeropositive subjectsElectrophysiologic abnormalitiesHIV infectionStudy cohortNeurologic diseaseSystem abnormalitiesHomosexual menCell countSerologic groupsCohortAbnormalitiesClear associationNeuropsychological tests